Glenmark Pharmaceuticals has received the USFDA final approval for its anti-bacterial drug Zyvox. The product is the therapeutic equivalent of Zyvox tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer. According to sales data estimates, sales for the 12 months to October 2015, Zyvox tablets, 600 mg is likely to be around $447.6 million. Zyvox is an anti-bacterial drug marked for adults and children for the treatment of infections such as pneumonia, complicated skin and skin structure infections, including diabetic foot infections.
Company Profile : Glenmark Pharma Ltd
Leave a Reply